Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.

Autor: Gajbhiye KR; Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth, Erandwane, Pune, 411038, India., Salve R; Nanobioscience, Agharkar Research Institute, Pune, 411038, India.; Savitribai Phule Pune University, Pune, 411007, India., Narwade M; Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth, Erandwane, Pune, 411038, India., Sheikh A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. prashantdops@gmail.com.; Center for Global health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India. prashantdops@gmail.com., Gajbhiye V; Nanobioscience, Agharkar Research Institute, Pune, 411038, India. cme_virendra@yahoo.co.in.; Savitribai Phule Pune University, Pune, 411007, India. cme_virendra@yahoo.co.in.
Jazyk: angličtina
Zdroj: Molecular cancer [Mol Cancer] 2023 Oct 03; Vol. 22 (1), pp. 160. Date of Electronic Publication: 2023 Oct 03.
DOI: 10.1186/s12943-023-01849-0
Abstrakt: Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hybrid nanoparticles (LPHNPs) are advanced core-shell nanoconstructs with a polymeric core region enclosed by a lipidic layer, presumed to be derived from both liposomes and polymeric nanounits. This unique concept is of utmost importance as a combinable drug delivery platform in oncology due to its dual structured character. To add advantage and restrict one's limitation by other, LPHNPs have been designed so to gain number of advantages such as stability, high loading of cargo, increased biocompatibility, rate-limiting controlled release, and elevated drug half-lives as well as therapeutic effectiveness while minimizing their drawbacks. The outer shell, in particular, can be functionalized in a variety of ways with stimuli-responsive moieties and ligands to provide intelligent holding and for active targeting of antineoplastic medicines, transport of genes, and theragnostic. This review comprehensively provides insight into recent substantial advancements in developing strategies for treating various cancer using LPHNPs. The bioactivity assessment factors have also been highlighted with a discussion of LPHNPs future clinical prospects.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje